Metropolitan Life Insurance Company (MetLife)’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-4,261
| Closed | -$4.1M | – | 1657 |
|
|
2024
Q1 | $4.1M | Sell |
4,261
-100
| -2% | -$95.1K | 0.18% | 102 |
|
|
2023
Q4 | $3.83M | Sell |
4,361
-56
| -1% | -$46.1K | 0.18% | 105 |
|
|
2023
Q3 | $3.64M | Sell |
4,417
-286
| -6% | -$225K | 0.19% | 96 |
|
|
2023
Q2 | $3.38M | Sell |
4,703
-107
| -2% | -$82.5K | 0.16% | 111 |
|
|
2023
Q1 | $3.95M | Sell |
4,810
-1,133
| -19% | -$855K | 0.2% | 97 |
|
|
2022
Q4 | $4.29M | Sell |
5,943
-212
| -3% | -$156K | 0.19% | 108 |
|
|
2022
Q3 | $4.24M | Sell |
6,155
-125
| -2% | -$78.7K | 0.2% | 101 |
|
|
2022
Q2 | $3.71M | Sell |
6,280
-81
| -1% | -$52.7K | 0.16% | 127 |
|
|
2022
Q1 | $4.44M | Sell |
6,361
-5,896
| -48% | -$3.73M | 0.16% | 123 |
|
|
2021
Q4 | $7.74M | Sell |
12,257
-287
| -2% | -$176K | 0.11% | 152 |
|
|
2021
Q3 | $7.59M | Sell |
12,544
-392
| -3% | -$243K | 0.11% | 145 |
|
|
2021
Q2 | $7.23M | Sell |
12,936
-4,717
| -27% | -$2.39M | 0.1% | 155 |
|
|
2021
Q1 | $8.35M | Sell |
17,653
-988
| -5% | -$481K | 0.12% | 141 |
|
|
2020
Q4 | $9.01M | Sell |
18,641
-819
| -4% | -$442K | 0.13% | 124 |
|
|
2020
Q3 | $10.9M | Sell |
19,460
-354
| -2% | -$215K | 0.18% | 89 |
|
|
2020
Q2 | $12.4M | Buy |
19,814
+7,059
| +55% | +$4.01M | 0.22% | 82 |
|
|
2020
Q1 | $6.23M | Sell |
12,755
-83
| -0.6% | -$34.2K | 0.13% | 148 |
|
|
2019
Q4 | $4.82M | Sell |
12,838
-16
| -0.1% | -$5.38K | 0.08% | 217 |
|
|
2019
Q3 | $3.57M | Sell |
12,854
-2,945
| -19% | -$871K | 0.06% | 273 |
|
|
2019
Q2 | $4.95M | Buy |
15,799
+746
| +5% | +$248K | 0.08% | 213 |
|
|
2019
Q1 | $6.18M | Sell |
15,053
-329
| -2% | -$135K | 0.11% | 155 |
|
|
2018
Q4 | $5.75M | Buy |
15,382
+35
| +0.2% | +$12.8K | 0.12% | 155 |
|
|
2018
Q3 | $6.2M | Sell |
15,347
-338
| -2% | -$129K | 0.11% | 169 |
|
|
2018
Q2 | $5.41M | Buy |
15,685
+177
| +1% | +$55.4K | 0.09% | 195 |
|
|
2018
Q1 | $5.34M | Buy |
15,508
+93
| +0.6% | +$32.3K | 0.08% | 208 |
|
|
2017
Q4 | $5.79M | Sell |
15,415
-24,438
| -61% | -$9.9M | 0.08% | 190 |
|
|
2017
Q3 | $17.8M | Sell |
39,853
-216
| -0.5% | -$103K | 0.11% | 160 |
|
|
2017
Q2 | $19.7M | Sell |
40,069
-544
| -1% | -$238K | 0.14% | 140 |
|
|
2017
Q1 | $15.7M | Sell |
40,613
-348
| -0.8% | -$129K | 0.11% | 170 |
|
|
2016
Q4 | $15M | Sell |
40,961
-1,086
| -3% | -$413K | 0.11% | 178 |
|
|
2016
Q3 | $16.9M | Sell |
42,047
-1,760
| -4% | -$706K | 0.12% | 156 |
|
|
2016
Q2 | $15.3M | Sell |
43,807
-507
| -1% | -$195K | 0.11% | 168 |
|
|
2016
Q1 | $16M | Sell |
44,314
-375
| -0.8% | -$155K | 0.12% | 154 |
|
|
2015
Q4 | $24.3M | Sell |
44,689
-384
| -0.9% | -$208K | 0.19% | 104 |
|
|
2015
Q3 | $21M | Buy |
45,073
+229
| +0.5% | +$123K | 0.15% | 132 |
|
|
2015
Q2 | $22.9M | Buy |
+44,844
| New | +$21.9M | 0.16% | 131 |
|
|
2015
Q1 | – | Sell |
-44,487
| Closed | -$18.3M | – | 2392 |
|
|
2014
Q4 | $18.3M | Buy |
44,487
+84
| +0.2% | +$33K | 0.13% | 160 |
|
|
2014
Q3 | $16M | Sell |
44,403
-3,895
| -8% | -$1.31M | 0.12% | 177 |
|
|
2014
Q2 | $13.6M | Sell |
48,298
-1,787
| -4% | -$530K | 0.09% | 218 |
|
|
2014
Q1 | $15M | Sell |
50,085
-649
| -1% | -$200K | 0.1% | 195 |
|
|
2013
Q4 | $14M | Sell |
50,734
-672
| -1% | -$193K | 0.1% | 209 |
|
|
2013
Q3 | $16.1M | Buy |
51,406
+554
| +1% | +$146K | 0.12% | 155 |
|
|
2013
Q2 | $11.4M | Buy |
+50,852
| New | +$11.8M | 0.09% | 223 |
|
Other funds holding REGN
Metropolitan Life Insurance Company (MetLife)'s REGN Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 4,261 shares — an estimated $4.1M sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in REGN in Q2 2013 and held it in 43 quarters. The position peaked at $24.3M in Q4 2015. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 4,261 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $4.1M.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 43 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Regeneron Pharmaceuticals position peaked at $24.3M in Q4 2015.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.